RARA and acute promyelocytic leukemia: Furthermore, the first generation BCR-ABL1 TKI for chronic myeloid leukemia (CML) imatinib (STI571, Gleevec) potentiated pharmacological activity of retinoic acid in APL cells and affected degradation of RARα and PML-RARα [8–10].